Decent overview of the inhaled delivery space.
Holding Their Breath
No one is rooting harder for Exubera than manufacturers of inhaled-insulin therapies in late-stage clinical trials: Kos Pharmaceuticals, Mannkind Corporation, Novo Nordisk (which partners with Aradigm, based in Hayward, California), and Eli Lilly (which teamed up with Boston-base Alkermes). Nothing would have been worse for these companies than FDA's failure to approve Pfizer's drug. And now that Exubera is launched, few outcomes could derail the new products faster than a major setback for their biggest competitor. If Exubera puts physicians and patients at ease about the new insulin delivery system—and satisfies FDA that the new technology is safe—it will create a new market, for which all future inhaled-insulin products will compete.
Comments